CN109260229A - A kind of oral nutrient lotion comprising fish oil - Google Patents

A kind of oral nutrient lotion comprising fish oil Download PDF

Info

Publication number
CN109260229A
CN109260229A CN201810964699.1A CN201810964699A CN109260229A CN 109260229 A CN109260229 A CN 109260229A CN 201810964699 A CN201810964699 A CN 201810964699A CN 109260229 A CN109260229 A CN 109260229A
Authority
CN
China
Prior art keywords
fish oil
lotion
oil
oral nutrient
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810964699.1A
Other languages
Chinese (zh)
Inventor
甘莉
段小冬
刘月华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fu Cheng (shanghai) Pharmaceutical Technology Co Ltd
Original Assignee
Fu Cheng (shanghai) Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fu Cheng (shanghai) Pharmaceutical Technology Co Ltd filed Critical Fu Cheng (shanghai) Pharmaceutical Technology Co Ltd
Priority to CN201810964699.1A priority Critical patent/CN109260229A/en
Publication of CN109260229A publication Critical patent/CN109260229A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The oral nutrient lotion comprising fish oil that the present invention relates to a kind of comprising fish oil, lactalbumin and arginine and cinnamon oil.Fish Oil Emulsion can remain to reach excellent antioxidative stabilizer the case where not using antioxidant by using lactalbumin and arginine, and effectively reduce belch and offending taste that fish oil may cause.

Description

A kind of oral nutrient lotion comprising fish oil
Technical field
The present invention relates to a kind of nutritional supplements, and in particular to a kind of oral nutrient lotion comprising fish oil.
Background technique
Contain abundant fatty acid in fish oil, main active is w-3 polyunsaturated fatty acid, wherein again with DHA and Based on EPA, the mass fraction of DHA and EPA can achieve 25% ~ 35%, have enhancing memory, Adjust-blood lipid and anti-inflammatory anti- The pharmacological activity such as oxidation.
Lack omega-3 polyunsaturated fatty acids in diet or nutritious food, can lead to arachidonic acid and EPA ratio is lost It adjusts, causes PGs2, TXA2 etc. to increase, generate excessive stress reaction, and then lead to immunosupress, platelet aggregation and excessive Inflammatory reaction.While the ratio of EPA/AA is positively correlated in cell stability and membrane phospholipid, takes in the polyunsaturated fat containing ω -3 After sour nutriment, EPA and DHA can quickly replace part AA in membrane phospholipid, so that cell membrane fluidity be made to reduce, and then make it Attached wall, chemotactic, phagocytic function decline, to inhibit excessive inflammatory reaction, reduce the damage of immune system.
But currently, omega-3 polyunsaturated fatty acids (EPA/DHA) are more used in stomach as a kind of immune Metabolic intervention element Parenteral nutritional preparation, be applied to the urgent patients such as wound, burn, septicopyemia and have underfed tumour patient and The peri-operation period nutritional support of capital operation patient is reported and few for oral nutritional support research.
Due to omega-fatty acid and its metabolin be in nature it is anti-inflammatory, ω -6 fatty acid and its metabolin are substantially It is proinflammatory disease.The diet balance of ω -6/ ω -3 is always a problem, although the World Health Organization and FAO (Food and Agriculture Organization of the United Nation) push away The ratio recommended is 5~10: 1, and many researchs focus mostly in two classes for Effect study of ω -3 and ω -6 PUFA to angiogenesis The independent of substance quantifies, but still has arguement to their rational proportions in vivo.It is most of to think, omega 6 polyunsaturated fatty acid It should remove as far as possible, omega 6 polyunsaturated fatty acid, which can be metabolized, generates dienoic acid epoxides and tetraenoic acid lipid oxidation object, above-mentioned generation Thanking to product has the function of strong promotion inflammatory reaction, including vasoconstriction and smooth muscle, improves capillary permeability, promotees Into platelet aggregation, leukocyte chemotaxis effect and immunosupress.There are also studies have shown that ω -6 polyunsaturated fatty acid derivative It can promote the angiogenesis of tumour by the expression of the stimulating growth factor.
Some thinks, omega 6 polyunsaturated fatty acid be it is beneficial, need to keep in fish oil more than a certain amount of ω -6 not Saturated fatty acid reduces the horizontal of soluble A β as US2007032548 discloses the diet comprising DHA, although the work of DHA With weakening over time, especially in the individual that adrenic acid or arachidonic level improve or in DPAn-6 level In reduced individual.Over time, only comprising a diet of DHA be most effective, but at time point earlier, DHA and The combination of DPAn-6 is also that effectively, at early time point, DHA and ARA combination are also effective.With the animal for only feeding DHA When comparing, the animal for being provided with the DHA and DPAn-6 of sufficient diet has the DPAn-6 significantly improved horizontal in the tissue, Animal with higher blood DHA and ARA level is easy to reduce presenilin-1 more, although only including the diet or packet of DHA The diet combined containing DHA and DPAn-6 also makes the reduction of presenilin-1 level.However, including DHA's for phosphorylation tau protein Diet or diet comprising DHA and DPAn-6 all substantially reduce phosphorylation tau protein, or even at time point later, and DHA Combination with DPAn-6 is effective, and compared with the diet for being only rich in DHA, the combination of DHA and DPAn-6 are intended to more have Effect.I.e. the research thinks that the combination comprising omega 6 polyunsaturated fatty acid is more efficient to prevention senile dementia.
WO2016/071927 discloses the nutrient fat acid composition of optimization, ω -6 fatty acid in the composition with The ratio of omega-fatty acid is 1:1 to 1:1 .25, maintains the consumption of both required ω -6 and omega-fatty acid in the diet Balance is to increase, and development maintains health, the key of disease recovery and wound healing.
US5223285 discloses the liquid nutritional product containing fat source for nutrition, when being fed for consumptive When it can provide desired effect.The fat source has following [n- (6) and n- (3)] weight ratios, selected from linoleic acid (18: 2n6), the fatty acid of acid and gamma-linolenic (18: 3n6) and arachidonic acid (20: 4n6) be selected from alpha-linolenic acid (18: 3n3), 18 Carbon tetraenoic acid (18: 4n3), eicosapentaenoic acid (20: 5n3), clupanodonic acid (22: 5n3) and docosahexaenoic acid The ratio between the fatty acid of (22: 6n3) is about 1.5 to about 3.0.WO2004/004599, which is also disclosed, a kind of treats dry eyes, dry The nutrition fortifier that the method for illness, mainly application include n-6 fatty acid, while also containing n-3 fatty acid.
Thus, the ratio for how deploying ω -6/ ω -3 still has difficulty, in addition, while increasing ω -6 fatty acid, Unstable double bond is also increase accordingly, and unsaturated fatty acid faces the stability problem of Fish Oil Emulsion more because being oxidized easily Challenge, while also adding and overcoming the problems, such as oral fish oil taste, and flavor Resolving probiems are bad, and extreme influence consumer is connect It is spent.
Usually after fish oil intake, intake will appear belch (or reflux) phenomenon shortly after, lead to occurring one kind in the mouth Taste beastly, and occur a kind of very offensive odour in breathing, and even if work as this composition By it is no by chewing ground all swallow down when, such as even if fish oil is wrapped up with capsule after, this feelings can be occurred by remaining on Condition.Such as GB2349817 discloses a kind of Perle, capsule contents joined a kind of mandarin oil smoke agent for shielding, to reduce The aftertaste of return simultaneously reduces smell.CA2293088, which is also disclosed, mixes fish oil and thyme essence, mends to cover food Fill the fish oil aroma and flavor in drug.EP1351585 is also disclosed selected from parsley seed oil, balm, lemon grass (Cymbopogon citratus) simultaneously Smell-masking ingredient of oil, fennel oil, peppermint oil, menthol, emits bad smell to reduce fish oil, and after reduction intake Belch.However, in an experiment, it has been found that when fish oil ingredient changes, these ingredients such as parsley seed oil, lemon grass (Cymbopogon citratus) Oil, fennel oil, peppermint oil, mandarin oil not can solve the belch problem of fish oil.Therefore, when improving fish oil prescription, The challenge of stability is not only faced, the challenge of fish oil taste is also faced.
Summary of the invention
The present invention is in order to solve the above technical problems, the present invention provides the oral nutrient lotion comprising fish oil, the nutritional breast Liquid maintains a certain amount of ω -6 fatty acid, devises the ratio of more reasonable ω -6 fatty acid and omega-fatty acid, simultaneously The lotion has the function of excellent anti-peroxidation lipid, and can remove the unpleasant or even nauseous taste of fish oil well Road.
In order to realize the above technical effect, the oral nutrient lotion comprising fish oil that the present invention provides a kind of.
The present invention includes the oral nutrient lotion of fish oil comprising fish oil, lactalbumin and arginine.
Above-mentioned oral nutrient lotion, for the unpleasant taste for reducing fish oil, present invention employs lactalbumins and smart ammonia Acid, and cinnamon oil is further used, reduce fish oil and enters stomach and intestine still there may be the discomforts such as belch.
Above-mentioned oral nutrient lotion, the lotion do not include or can due to antioxidant application including antioxidant Unfavorable catalytic oxidation can occur with surfactant, albumen, the metal ion etc. in lotion, lead to unsaturated fatty acid The ingredient of new unpleasant taste is generated during being oxidized, for the introducing for reducing or avoiding antioxidant, the present invention is used Lactalbumin and arginine reduce or avoid the addition of antioxidant.
Above-mentioned antioxidant is selected from one of vitamin E, vitamin C, tea polyphenols or a variety of.
Oral nutrient lotion of the invention, further comprises deionized water.
Oral nutrient lotion of the invention further comprises one of sweetener, edible essence or a variety of, the sweet tea Taste agent is selected from Aspartame, steviol glycoside.
It is furthermore preferred that fish oil of the present invention contains 50% or more ω -3 polyunsaturated fatty acid, and ω -6 how unsaturated rouge The mass ratio of fat acid and omega-3 polyunsaturated fatty acids is (0.1-0.6): 10, preferably 0.3:10,0.4:10,0.5:10.
Further, ω -3 of the invention polyunsaturated fatty acid includes EPA and DHA, in terms of fish oil weight, the fish The DHA of EPA and 20%-60% of the oil comprising 30%-50%.
The present invention further provides with lotion total weight, it includes the fish oil of 20-40%, the arginine of 2-5%, 4-10% Lactalbumin, the cinnamon oil of 0.1-1%, 40-70% deionized water.More preferable 30% fish oil, 3.5% arginine, 5% whey egg It is white, 0.5% cinnamon oil, 40-70% deionized water.The steviol glycoside of 0.01-0.1% is more preferably further included, and further packet The vitamin E of vitamin C, 0.1-0.5% containing 0.1-0.5% or the tea polyphenols of 0.1-0.5%.
Oral nutrient lotion of the invention can be used to reduce the application of the lotion of neutral fat in blood lipid and blood in preparation. This hair oral nutrient lotion also has excellent antioxidative stabilizer, and interior propionic aldehyde is no more than in the content of lotion for 24 hours at 60 DEG C 30mg/kg, preferably at 60 DEG C in 48h propionic aldehyde lotion content be no more than 30mg/kg, at 60 DEG C in 72h propionic aldehyde in cream The content of liquid is no more than 30mg/kg；More preferably at 60 DEG C in 48h propionic aldehyde lotion content be no more than 20mg/kg；More preferably At 60 DEG C for 24 hours in propionic aldehyde lotion content be no more than 15mg/kg.
Technical effect of the invention:
1, Fish Oil Emulsion of the present invention can be remained to by using lactalbumin and arginine the case where not using antioxidant Reach excellent antioxidative stabilizer, and reduces and be oxidized possible unpleasant taste in the process.
2, Fish Oil Emulsion of the present invention further uses cinnamon oil, avoid fish oil after swallowing stomach and intestine still there may be Belch, and reduce unpleasant taste when taking.
3, Fish Oil Emulsion of the present invention can have the function of reducing blood lipid level and neutral fat in blood.
Specific embodiment
Embodiment 1:
The oral fish oil nutritional emulsions of the present embodiment: it is at being grouped as, in terms of 1000g total amount:
Fish oil 280g,
(in terms of fish oil quality total amount, contain EPA30.5%, DHA34.6%, wherein ω -6 polyunsaturated fatty acid: insatiable hunger more than ω -3 It is 0.5:10 with fatty acid mass ratio)；
Arginine 35g；
Lactalbumin 50g；
Cinnamon oil 5g；
Steviol glycoside 0.5g；
Deionized water 629.5g.
Preparation method:
At 45 DEG C, by 50g lactalbumin (lactalbumin contains 52% beta lactoglobulin, 35% α-lactalbumin), 35g arginine and 0.5g steviol glycoside with continuous stirring, are added in 629.5g deionized water, are stirred 30 minutes.So After be heated to keeping 10min at 60 DEG C, then place to room temperature and protein solution be prepared.By above-mentioned protein solution and fish oil And cinnamon oil mixing, it is homogenized twice in two-stage high-pressure homogenizer, wherein the first stage pressure is 200 bars, the second stage pressure is 40 Bar, finally use UHT at 70 DEG C by lotion pasteurize 15s.
Embodiment 2:
The oral fish oil nutritional emulsions of the present embodiment: it is at being grouped as, in terms of 1000g total amount:
Fish oil 300g,
(in terms of fish oil quality total amount, contain EPA32.5%, DHA40.2%, wherein ω -6 polyunsaturated fatty acid: insatiable hunger more than ω -3 It is 0.45:10 with fatty acid mass ratio)；
Arginine 30g；
Lactalbumin 55g；
Cinnamon oil 8g；
Steviol glycoside 0.5g；
Deionized water 606.5g.
Preparation method:
At 40 DEG C, by 55g lactalbumin (lactalbumin contains 52% beta lactoglobulin, 35% α-lactalbumin), 30g arginine and 0.5g steviol glycoside with continuous stirring, are added in 606.5g deionized water, are stirred 35 minutes.So After be heated to keeping 15min at 60 DEG C, then place to room temperature and protein solution be prepared.By above-mentioned protein solution and fish oil And cinnamon oil mixing, it is homogenized twice in two-stage high-pressure homogenizer, wherein the first stage pressure is 210 bars, the second stage pressure is 45 Bar, finally use UHT at 72 DEG C by lotion pasteurize 15s.
Embodiment 3:
The oral fish oil nutritional emulsions of the present embodiment: it is at being grouped as, in terms of 1000g total amount:
Fish oil 280g,
(in terms of fish oil quality total amount, contain EPA30.5%, DHA34.6%, wherein ω -6 polyunsaturated fatty acid: insatiable hunger more than ω -3 It is 0.5:10 with fatty acid mass ratio)；
Arginine 35g；
Lactalbumin 50g；
Cinnamon oil 5g；
Steviol glycoside 0.5g；
Vitamin E 2g；
Tea polyphenols 3.5g；
Deionized water 624g.
Preparation method:
At 45 DEG C, by 50g lactalbumin (lactalbumin contains 52% beta lactoglobulin, 35% α-lactalbumin), 35g arginine, 2g vitamin E, 3.5g tea polyphenols and 0.5g steviol glycoside with continuous stirring, are added in 624g deionization In water, stir 30 minutes.It is then heated at 60 DEG C and keeps 10min, then place to room temperature and protein solution is prepared.It will be upper It states protein solution to mix with fish oil and cinnamon oil, be homogenized twice in two-stage high-pressure homogenizer, wherein the first stage pressure is 200 Bar, the second stage pressure is 40 bars, finally uses UHT at 72 DEG C by lotion pasteurize 15s.
Embodiment 4:
The oral fish oil nutritional emulsions of the present embodiment: it is at being grouped as, in terms of 1000g total amount:
Fish oil 280g,
(in terms of fish oil quality total amount, contain EPA30.5%, DHA34.6%, wherein ω -6 polyunsaturated fatty acid: insatiable hunger more than ω -3 It is 0.5:10 with fatty acid mass ratio)；
Arginine 35g；
Lactalbumin 50g；
Cinnamon oil 5g；
Steviol glycoside 0.5g；
Vitamin c 1g；
Tea polyphenols 3.5g；
Deionized water 625g.
Preparation method:
At 45 DEG C, by 50g lactalbumin (lactalbumin contains 52% beta lactoglobulin, 35% α-lactalbumin), 35g arginine, 1g vitamin C, 3.5g tea polyphenols and 0.5g steviol glycoside with continuous stirring, are added in 625g deionization In water, stir 30 minutes.It is then heated at 60 DEG C and keeps 10min, then place to room temperature and protein solution is prepared.It will be upper It states protein solution to mix with fish oil and cinnamon oil, be homogenized twice in two-stage high-pressure homogenizer, wherein the first stage pressure is 220 Bar, the second stage pressure is 50 bars, finally uses UHT at 70 DEG C by lotion pasteurize 15s.
Embodiment 5:
The oral fish oil nutritional emulsions of the present embodiment: it is at being grouped as, in terms of 1000g total amount:
Fish oil 310g,
(in terms of fish oil quality total amount, contain EPA35.2%, DHA36.7%, wherein ω -6 polyunsaturated fatty acid: insatiable hunger more than ω -3 It is 0.32:10 with fatty acid mass ratio)；
Arginine 30g；
Lactalbumin 55g；
Cinnamon oil 4g；
Steviol glycoside 0.5g；
Vitamin c 1g；
Tea polyphenols 3.5g；
Edible essence 0.5g；
Deionized water 595.5g.
Preparation method:
At 45 DEG C, by lactalbumin (lactalbumin contains 52% beta lactoglobulin, 35% α-lactalbumin), smart ammonia Acid, vitamin C, tea polyphenols and steviol glycoside and essence with continuous stirring, are add to deionized water, and are stirred 35 minutes. It is then heated at 60 DEG C and keeps 15min, then place to room temperature and protein solution is prepared.By above-mentioned protein solution and fish Oil and cinnamon oil mixing, homogenize twice in two-stage high-pressure homogenizer, wherein the first stage pressure is 220 bars, the second stage pressure is 50 bars, finally use UHT at 70 DEG C by lotion pasteurize 15s.
Embodiment 6:
Lactalbumin in embodiment 1 is substituted for Tween-80, remaining is same as Example 1.
Embodiment 7:
Arginine in embodiment 1 is removed into (after removal, the dosage of deionized water increase accordingly 30g), remaining and 1 phase of embodiment Together.
Embodiment 8:
Cinnamon oil in embodiment 1 is substituted for peppermint oil, remaining is same as Example 1.
Embodiment 9:
Cinnamon oil in embodiment 1 is substituted for lemon oil, remaining is same as Example 1.
Embodiment 10:
Cinnamon oil in embodiment 1 is substituted for mandarin oil, remaining is same as Example 1.
Experimental example 1:
The stability study of the oxidable lipid of stability experiment-, with the dense of omega-3 polyunsaturated fatty acids oxidized byproduct propionic aldehyde Degree.It is detected, is measured using Supelcowax10 capillary column (30m, 0.32id, 0.5um film), by 3g lotion with gas chromatography The incubated samples at 50 DEG C are sealed to after vial, then solid phase microextraction is carried out using SPME fiber and prepares sample liquid, and Measure propanal concentration.Detection content: respectively Example 1,2,6,7 lotion, and measure respectively at 60 DEG C store 0h, for 24 hours, Propanal concentration after 48h, 72h.
1 lotion antioxidative stabilizer experimental result of table
The above result shows that also can even if the present invention uses lactalbumin and arginine under conditions of not using antioxidant The oxidative degradation of effective confrontation omega-3 polyunsaturated fatty acids, while using general ionic surface active agent or not using The lotion of arginic amino acid preparation is significantly less than reality at propionic aldehyde effect in reduction omega-3 polyunsaturated fatty acids oxidative degradation Apply the stabilizing effect of example 1.
Experimental example 2:
Taste and belch test experiments
Have chosen 30 subjects in this experiment, take the nutritional emulsions of embodiment 1,6,7,8,9,10 every other day respectively, record by Examination person reacts taste and stomach.
2 taste of table and belch test experiments result
Sample Belch number in 2 hours Taste dislikes nauseous number Feel obvious fishlike smell number Slight fishlike smell number Fishlike smell number is not felt
Embodiment 1 0 0 0 6 24
Embodiment 6 0 0 1 10 19
Embodiment 7 1 0 3 22 5
Embodiment 8 5 8 15 7 0
Embodiment 9 4 7 16 7 0
Embodiment 10 5 7 19 4 0
The above results show that peppermint oil, lemon oil, mandarin oil and fish oil prescription compatibility of medicines of the invention are difficult to solve fish oil taste Problem, there are still larger problems, while common surfactant is compared with lactalbumin using arginine, more can effectively encapsulate Fish oil improves the acceptability of user, and taste more makes us receiving, and is not in the smell for being difficult to receive.
Experimental example 3:
Mouse: being received semi-synthetic 15% cocoa butter of Western- type diet by HypercholesterolemicRats experiment, 40% sucrose and 0.25% cholesterol), every group 10, feed 4 weeks after, then respectively feed embodiment 1 lotion and fenofibrate 3 weeks, wherein It is normally fed after control group modeling, then measures plasma cholesterol, triglycerides the situation of change [(blood plasma level-of t=0 respectively The blood plasma level of t=3)/t=0 blood plasma level].Table 3 the result shows that, nutrition oral latex emulsion of the invention with lipid reduce Effect.
Plasma cholesterol, triglycerides after the treatment of table 33 weeks change percentage
Group Plasma cholesterol changes percentage Plasma triglyceride changes percentage
Control group 5.67% 4.52%
Embodiment 1 28.2% 22.1%
Fenofibrate 34.3% 37.8%

Claims (10)

1. a kind of oral nutrient lotion comprising fish oil, which is characterized in that it includes fish oil, lactalbumin and arginine.
2. oral nutrient lotion according to claim 1, which is characterized in that it further comprises cinnamon oil.
3. oral nutrient lotion according to claim 1, which is characterized in that the lotion does not include antioxidant.
4. oral nutrient lotion according to claim 1, which is characterized in that the lotion includes antioxidant.
5. according to oral nutrient lotion described in claim 3,4 any one, which is characterized in that the antioxidant is selected from dimension One of raw element E, vitamin C, tea polyphenols are a variety of.
6. oral nutrient lotion according to claim 1, which is characterized in that it further comprises deionized water.
7. oral nutrient lotion according to claim 1, which is characterized in that the ω -3 that the fish oil contains 50% or more is more Unsaturated fatty acid, and the mass ratio of omega 6 polyunsaturated fatty acid and omega-3 polyunsaturated fatty acids is (0.1-0.6): 10.
8. oral nutrient lotion according to claim 7, which is characterized in that ω -3 polyunsaturated fatty acid includes EPA and DHA, in terms of fish oil weight, the fish oil includes the DHA of the EPA and 20%-60% of 30%-50%.
9. oral nutrient lotion according to claim 2, which is characterized in that with lotion total weight, it includes 20-40% Fish oil, the arginine of 2-5%, the lactalbumin of 4-10%, the cinnamon oil of 0.1-1%, 40-70% deionized water.
10. oral nutrient lotion described in -9 any one reduces neutral fats in blood lipid and blood in preparation according to claim 1 The application of the lotion of fat.
CN201810964699.1A 2018-08-23 2018-08-23 A kind of oral nutrient lotion comprising fish oil Pending CN109260229A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810964699.1A CN109260229A (en) 2018-08-23 2018-08-23 A kind of oral nutrient lotion comprising fish oil

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810964699.1A CN109260229A (en) 2018-08-23 2018-08-23 A kind of oral nutrient lotion comprising fish oil

Publications (1)

Publication Number Publication Date
CN109260229A true CN109260229A (en) 2019-01-25

Family

ID=65154076

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810964699.1A Pending CN109260229A (en) 2018-08-23 2018-08-23 A kind of oral nutrient lotion comprising fish oil

Country Status (1)

Country Link
CN (1) CN109260229A (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106296A (en) * 1993-09-08 1995-08-09 山道士营养有限公司 Nutritional Supplement
CN1181909A (en) * 1997-12-17 1998-05-20 易琴华 Scented Yugui distillate and its preparation process
EP1112006A2 (en) * 1998-05-01 2001-07-04 Abbott Laboratories Elemental enteral nutritional product containing hydrolysed soy protein and partially hydrolysed caseinate
TW491693B (en) * 1997-04-21 2002-06-21 Viva America Marketing Inc Nutritive composition for cardiovascular health
TW200726407A (en) * 2006-01-02 2007-07-16 Standard Foods Corp Editable oil composition containing DHA
TW200803879A (en) * 2006-05-29 2008-01-16 Nat Agriculture & Food Res Organization Composition for improvement of lipid metabolism
TW201438586A (en) * 2013-04-12 2014-10-16 Tci Co Ltd A compound containing fish oil and the processing method thereof
CN105410932A (en) * 2015-11-03 2016-03-23 北京赛升药业股份有限公司 Tumor immunity type nutritional composition and application thereof
CN105658073A (en) * 2013-10-08 2016-06-08 太阳化学株式会社 Oil/fat composition containing polyunsaturated fatty acid
CN107969506A (en) * 2017-11-29 2018-05-01 山东禹王制药有限公司 A kind of high stability fish oil breast for improving glycometabolism and preparation method thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106296A (en) * 1993-09-08 1995-08-09 山道士营养有限公司 Nutritional Supplement
TW491693B (en) * 1997-04-21 2002-06-21 Viva America Marketing Inc Nutritive composition for cardiovascular health
CN1181909A (en) * 1997-12-17 1998-05-20 易琴华 Scented Yugui distillate and its preparation process
EP1112006A2 (en) * 1998-05-01 2001-07-04 Abbott Laboratories Elemental enteral nutritional product containing hydrolysed soy protein and partially hydrolysed caseinate
TW200726407A (en) * 2006-01-02 2007-07-16 Standard Foods Corp Editable oil composition containing DHA
TW200803879A (en) * 2006-05-29 2008-01-16 Nat Agriculture & Food Res Organization Composition for improvement of lipid metabolism
TW201438586A (en) * 2013-04-12 2014-10-16 Tci Co Ltd A compound containing fish oil and the processing method thereof
CN105658073A (en) * 2013-10-08 2016-06-08 太阳化学株式会社 Oil/fat composition containing polyunsaturated fatty acid
CN105410932A (en) * 2015-11-03 2016-03-23 北京赛升药业股份有限公司 Tumor immunity type nutritional composition and application thereof
CN107969506A (en) * 2017-11-29 2018-05-01 山东禹王制药有限公司 A kind of high stability fish oil breast for improving glycometabolism and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
余德林等: "紫苏籽油与红花籽油联合使用降血脂研究", 《中国油脂》 *
刘晓华等: "精氨酸-共轭亚油酸抗氧化活性研究", 《食品与发酵工业》 *
王萍等: "多不饱和脂肪酸的研究进展", 《中国油脂》 *
许鹏: "赖氨酸/精氨酸对乳化香肠脂肪和蛋白质氧化及品质影响的研究", 《中国优秀硕士学位论文全文数据库 工程科技I辑》 *

Similar Documents

Publication Publication Date Title
Patel et al. Futuristic food fortification with a balanced ratio of dietary ω-3/ω-6 omega fatty acids for the prevention of lifestyle diseases
Hageman et al. Comparison of bovine milk fat and vegetable fat for infant formula: Implications for infant health
DE69935995T2 (en) POLYUNGATURATED FATTY ACIDS NUTRITIONAL SUPPLEMENT
CN101325882B (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
JP5025657B2 (en) Compositions containing whey proteins and lipids and methods for preparing them
US9179702B2 (en) Liquid nutritional compositions containing unsaturated fatty acids
JP2002053892A (en) Oil or fat composition
KR20180004096A (en) Optimized nutritional fatty acid composition
JP2001526908A (en) Fat blend
TW201306752A (en) Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
PT1662904E (en) Compositions containing as the active ingredient componantes from salvia sclarea seed
CN103442593A (en) Nutritional products comprising beta-ydroxy-beta-methylbutyrate
CN102918140B (en) The method processing edible oil
TWI659748B (en) Oral composition
JP2001275614A (en) Mammalian milk-derived phospholipid-containing oral composition
JPS6344843A (en) O/w/o-type emulsified oil and fat composition
US20070280998A1 (en) Dairy product
RU2666190C2 (en) Composition containing iron sucrose and high-concentrated microencapsulated lcpusfa, with reduced foreign flavor
JPS6115647A (en) Oil and fat food
CN109260229A (en) A kind of oral nutrient lotion comprising fish oil
JPH09201A (en) Food for inflammatory intestine disease
JPS6344842A (en) O/w/o-type emulsified oil and fat composition
AU2017323114B2 (en) Fish odor-free fish oil composition and preparation method therefor
JP2006022068A (en) Serum lipid metabolism ameliorative agent
Olson et al. Omega-3 polyunsaturated fatty acids added to yogurt

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190125

RJ01 Rejection of invention patent application after publication